Training for those who administer cosmetic injections is lacking, despite significant growth in demand for fillers in the aesthetic medicine industry.

Conversations in Dermatology: 2025 will focus on clinical challenges and recent advances that health care providers who manage chronic pruritic conditions should know.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

AI can determine eczema severity from images, with results correlating with severity assigned by board-certified clinicians.

A new COVID-19 variant, NB.1.8.1, has spread in the Mediterranean, Southeast Asia, and Western Pacific regions.

The FDA has announced its plan for systematically reviewing food additives already commercially available for the first time.